Strategic Intelligence: Modality Intelligence - From Pipeline to Capital
Summary
Antibodies lead pipeline volume and forecast sales, and drive approvals alongside recombinants, but oligonucleotides are scaling fastest off a smaller base.Maturity and innovation stage, not pipeline size, determine where capital lands next.
Capital is consolidating around modalities with proven commercial models, and the cost of entry into mAbs, ADCs, siRNA, and BsAbs is rising across M&A, licensing, and VC alike.
Within mAbs and recombinants, capital is rotating out of mature mAb mega-deals and into early-stage ADC and recombinant platform bets, with buyers paying up front rather than waiting for clinical proof.
Scope
- This report talks about the different modalities within the pharma pipeline, showing how antibodies are dominating while other modalities, including GLP-1 peptides are forecast to generate signficant revenue within the next few years. As capital concentrates on proven winners, licesning has overtaken M&A as the preferred route to access innovation.
Reasons to Buy
- This report talks about the different modalities within the pharma pipeline, showing how antibodies are dominating while other modalities, including GLP-1 peptides are forecast to generate signficant revenue within the next few years. As capital concentrates on proven winners, licesning has overtaken M&A as the preferred route to access innovation.
Table of Contents
- Executive Summary
- Introduction
- Landscape
- Deep-Dive
- Deal-Making
- Top 3 Modalities Across Each Deal Type
- Strategic Implications
- Key Takeaways
- Appendix
- Abbreviations
- Related Reports
- Authors
- Contact Us
